Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | recruiting | Phase 2 | 96 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT07250477 | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 56 | University of California, DavisOTHER | 1 | Aug 25, 2026 |
| NCT07412262 | A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression(NSCLC, YAP) | recruiting | Phase 2 | 32 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 24, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT04310020 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | active not recruiting | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | suspended | Phase 2 | 63 | Duke UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 24, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 159 | Yale UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04933903 | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | recruiting | Phase 2 | 25 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | suspended | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07133425 | A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07329322 | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | not yet recruiting | Phase 2 | 35 | Mark BernardOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775040 | Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial | not yet recruiting | Phase 2 | 43 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777614 | OPTIMISE Lung SABR | not yet recruiting | Phase 2 | 208 | Cancer Trials IrelandNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT06194448 | To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations(NEOLA) | active not recruiting | Phase 2 | 76 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT07017829 | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07246863 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 131 | CatalYm GmbHINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774520 | A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy | recruiting | Phase 2 | 1,173 | Samsung Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03728361 | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | completed | Phase 2 | 55 | Dwight OwenOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | active not recruiting | Phase 2 / Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06514027 | Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations | recruiting | Phase 2 | 30 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06731907 | A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | recruiting | Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT07771764 | A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00180856 | Radiofrequency Ablation of Lung Tumors | completed | Phase 2 | 60 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01159288 | Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes(CSET 1437) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | active not recruiting | Phase 2 | 10 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT02994576 | Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer(PRINCEPS) | completed | Phase 2 | 60 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03965468 | Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC(CHESS) | active not recruiting | Phase 2 | 96 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer(ALISCA-Lung1) | recruiting | Phase 2 | 120 | Puma Biotechnology, Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | recruiting | Phase 1 / Phase 2 | 201 | Yuhan CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309) | active not recruiting | Phase 2 | 252 | AmgenINDUSTRY | 16 | Aug 17, 2026 | clinicaltrials |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05348668 | Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 78 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials